References
- Atanackovic D, Luetkens T, Kröger N. Coinhibitory molecule PD-1 as a potential target for the immunotherapy of multiple myeloma. Leukemia 2014; 28: 993–1000.
- Morgan GJ, Walker BA, Davies FE. The genetic architecture of multiple myeloma. Nat Rev Cancer 2010; 12: 335–348.
- Kay NE, Leong TL, Bone N, et al. Blood levels of immune cells predict survival in myeloma patients: results of an Eastern Cooperative Oncology Group phase 3 trial for newly diagnosed multiple myeloma patients. Blood 2001; 98: 23–28.
- Raitakari M, Brown RD, Gibson J, et al. T cells in myeloma. Hematol Oncol 2003; 21: 33–42.
- Corso A, Castelli G, Pagnucco G, et al. Bone marrow T-cell subsets in patients with monoclonal gammopathies: correlation with clinical stage and disease status. Haematologica 1997; 82: 43–46.
- Shin SJ, Roh J, Kim M, et al. Prognostic significance of absolute lymphocyte count/absolute monocyte count ratio at diagnosis in patients with multiple myeloma. Korean J Pathol 2013; 47: 526–533.
- Muthu Raja KR, Rihova L, Zahradova L, et al. Increased T regulatory cells are associated with adverse clinical features and predict progression in multiple myeloma. PLoS One 2012; 7(10):e47077.
- Muthu Raja KR, Kubiczkova L, Rihova L, et al. Functionally suppressive CD8 T regulatory cells are increased in patients with multiple myeloma: a cause for immune impairment. PLoS One 2012; 7(11):e49446.
- Prabhala RH, Neri P, Bae JE, et al. Dysfunctional T regulatory cells in multiple myeloma. Blood 2006; 107: 301–304
- Talebian L, Fischer DA, Wu J, et al. The natural killer-activating receptor, NKG2D, on CD3 + CD8 + T cells plays a critical role in identifying and killing autologous myeloma cells. Transfusion 2014; 54: 1515–1521.
- Leone P, Berardi S, Frassanito MA, et al. Dendritic cells accumulate in the bone marrow of myeloma patients where they protect tumor plasma cells from CD8 + T cell killing. Blood. 2015; 126: 1443–1451.
- Pessoa de Magalhães RJ, Vidriales MB, Paiva B, et al.; Spanish Myeloma Group (GEM); Grupo Castellano-Leones de Gammapatias Monoclonales, cooperative study groups. Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry. Haematologica 2013; 98: 79–86.
- Haabeth OA, Tveita AA, Fauskanger M, et al. How do CD4(+) t cells detect and eliminate tumor cells that either lack or express MHC class II molecules? Front Immunol 2014; 5: 174. doi: 10.3389/fimmu.2014.00174.
- De Keersmaecker B, Fostier K, Corthals J, et al. Immunomodulatory drugs improve the immune environment for dendritic cell-based immunotherapy in multiple myeloma patients after autologous stem cell transplantation. Cancer Immunol Immunother 2014; 63: 1023–1036.
- Quach H, Ritchie D, Stewart AK, et al. Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma Leukemia 2010; 24: 22–32.